Cargando…
Efficacy and Safety of Apatinib for Elderly Patients with Advanced or Metastatic Gastric Cancer After Failure of at Least First-Line Chemotherapy: A Multi-Center, Single-Arm, Phase II Study
BACKGROUND: Apatinib improves progression-free survival and overall survival with an acceptable safety profile in Chinese patients with chemotherapy-refractory advanced or metastatic gastric cancer. However, the efficacy and safety of apatinib are unclear for elderly patients. This study was underta...
Autores principales: | Ren, Dengfeng, Wang, Guoxiu, Zhang, Yu, Kan, Jie, Dong, Qiuxia, Zhao, Junhui, Ji, Faxiang, Li, Hao, Luo, Yushuang, Lin, Mingzhe, Li, Guoyuan, Liu, Zhibo, Ma, Xinfu, Guo, Qijing, Zhao, Fuxing, Shen, Guoshuang, Zhao, Jiuda |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380789/ https://www.ncbi.nlm.nih.gov/pubmed/34434051 http://dx.doi.org/10.2147/OTT.S322710 |
Ejemplares similares
-
A comparison between triplet and doublet chemotherapy in improving the survival of patients with advanced gastric cancer: a systematic review and meta-analysis
por: Guo, Xinjian, et al.
Publicado: (2019) -
A Single‐Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer
por: Chen, Xiaofeng, et al.
Publicado: (2019) -
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
por: Shen, Guoshuang, et al.
Publicado: (2018) -
Meta-Analysis of HER2-Enriched Subtype Predicting the Pathological Complete Response Within HER2-Positive Breast Cancer in Patients Who Received Neoadjuvant Treatment
por: Shen, Guoshuang, et al.
Publicado: (2021) -
Treatment options for patients with human epidermal growth factor 2-positive breast cancer brain metastases: A systematic review and meta-analysis
por: Huo, Xingfa, et al.
Publicado: (2023)